Article Text

Download PDFPDF
Medicines optimisation: time to review fibrates?
  1. Teck K Khong, DTB Associate Editor
  1. Department of Clinical Pharmacology, St George's University of London, London, UK
  1. Correspondence to Dr Teck K Khong, Clinical Pharmacology, Institute of Medical & Biomedical Institute, St George's University of London, London, UK; tkhong{at}sgul.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In grappling with the challenge of maximising health outcomes from increasingly stretched and finite resources, healthcare systems have been developing and implementing strategies to improve the use of medicines. In the NHS over the past decade, there has been growing attention on medicines optimisation. Defined as ‘a person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines’, medicines optimisation has an emphasis on safety, governance, professional collaboration and patient engagement.1 2 For the practitioner trying to do the best for their patient, this may sound somewhat like an initiative imposed by a top-down, management- and process-heavy organisation unresponsive to the realities of daily operational issues, bureaucracy and the pressures faced by …

View Full Text

Footnotes

  • Competing interest None declared. Refer to the online supplementary files to view the ICMJE form(s).